Raptor Announces Full Enrollment of Phase 2b Trial of RP103 for Non-Alcoholic Fatty Liver Disease in Children
January 13, 2014 07:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103...